FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Seidman

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Activities & Behaviors

Clinical Trials, Phase II as Topic

Co-author Network

Publications

TOP 3
Andrew D Seidman
The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?
Xi Chen; Christian M Custodio; Clifford A Hudis; Andrew D Seidman; Michael D Stubblefield; Lisa M DeAngelis
Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer.
Conleth G Murphy; Sujata Patil; Nancy Sklarin; Samantha Stein; Mary L Gemignani; Jane Howard; Clifford A Hudis; Divya Mallam; Andrew D Seidman
Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Seidman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andrew D Seidman
The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(14):1707-8.
2013: Xi Chen; Christian M Custodio; Clifford A Hudis; Andrew D Seidman; Michael D Stubblefield; Lisa M DeAngelis
Electrophysiological features of taxane-induced polyneuropathy in patients with breast cancer.
Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2013;30(2):199-203.
2012: Conleth G Murphy; Sujata Patil; Nancy Sklarin; Samantha Stein; Mary L Gemignani; Jane Howard; Clifford A Hudis; Divya Mallam; Andrew D Seidman
Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer.
Cancer 2012;118(13):3254-9.
2012: S M Lichtman; Hyman Muss; Andrew D Seidman; E Winer; C T Cirrincione; H J Cohen; Clifford Hudis; Arti Hurria
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(3):632-8.
2011: Monica Fornier; Teresa A Gilewski; A Abbruzzi; Jacqueline F Bromberg; J Chang; Gabriella D'Andrea-Carlino; Chau Dang; Maura Dickler; S Modi; P G Morris; Larry Norton; Andrew D Seidman; Nancy T Sklarin; Clifford Hudis
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2575-81.
2011: Andrew D Seidman; A Brufsky; R H Ansari; L L Hart; R S Stein; L S Schwartzberg; J F Stewart; C A Russell; S-C Chen; L E Fein; J A De La Cruz Vargas; S-B Kim; J Cavalheiro; L Zhao; J F Gill; Coleman K Obasaju; Mauro Orlando; D F Tai
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(5):1094-101.
2011: mustafa khasraw; Edi Brogi; Andrew D Seidman
The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
Current oncology reports 2011;13(1):17-25.
2010: Pamela Drullinsky; Steven M Sugarman; Monica N Fornier; Gabriella D'Andrea-Carlino; Teresa Gilewski; Diana Lake; Tiffany Traina; Carolyn Wasserheit-Lieblich; Nancy Sklarin; Deena Atieh-Graham; Nancy Mills; Tiffany Troso-Sandoval; Andrew D Seidman; Jeffrey Yuan; Hamangi Patel; Sujata Patil; Larry Norton; Clifford Hudis
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Clinical breast cancer 2010;10(6):440-4.
2010: Andrew D Seidman
Brain metastases from breast cancer.
Clinical advances in hematology & oncology : H&O 2010;8(9):595-7.
2010: Devika Gajria; Andrew D Seidman; Chau Dang
Adjuvant taxanes: more to the story.
Clinical breast cancer 2010;10 Suppl 2():S41-9.
2010: Alison K Conlin; Andrew D Seidman; Ariadne M Bach; Diana Lake; Maura Dickler; Gabriella D'Andrea-Carlino; Tiffany A Traina; Michael Danso; Adam M Brufsky; Mansoor Saleh; Alicia Clawson; Clifford Hudis
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Clinical breast cancer 2010;10(4):281-7.
2010: Mary Morrogh; Thomas J Miner; Anna Park; Ann Jenckes; Mithat Gonen; Andrew D Seidman; Monica Morrow; David P Jaques; Tari A King
A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer.
Cancer 2010;116(14):3338-47.
2010: C G Murphy; mustafa khasraw; Andrew D Seidman
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
Breast cancer research and treatment 2010;122(1):177-9.
2010: Hong Lin; Elisa de Stanchina; Xi Kathy Zhou; Feng Hong; Andrew D Seidman; Monica Fornier; Wei-Lie Xiao; Edward J Kennelly; Kathleen Wesa; Barrie R Cassileth; Susanna Cunningham Rundles
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity.
Cancer immunology, immunotherapy : CII 2010;59(6):885-97.
2010: Stacy L Moulder; Frankie A Holmes; Anthony W Tolcher; Peter F Thall; Kristine Broglio; Vicente Valero; Aman U Buzdar; Susan G Arbuck; Andrew D Seidman; Gabriel N Hortobagyi
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
Cancer 2010;116(4):814-21.
2010: Tiffany A Traina; Hope S Rugo; James Caravelli; Sujata M Patil; Benjamin Yeh; Michele E Melisko; John W Park; Stephanie Geneus; Matthew Paulson; Jill Grothusen; Andrew D Seidman; Monica Fornier; Diana E Lake; Chau Dang; Mark Robson; Maria Theodoulou-Haber; Carlos D Flombaum; Larry Norton; Clifford Hudis; Maura Dickler
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):628-33.
2009: Gary Deng; Hong Lin; Andrew D Seidman; Monica Fornier; Gabriella D'Andrea-Carlino; Kathleen Wesa; Simon Yeung; Susanna Cunningham Rundles; Andrew J Vickers; Barrie R Cassileth
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects.
Journal of cancer research and clinical oncology 2009;135(9):1215-21.
2009: Conleth G Murphy; Andrew D Seidman
Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
Clinical breast cancer 2009;9 Suppl 2():S58-65.
2008: Maura Dickler; Hope S Rugo; Carey A Eberle; Edi Brogi; James Caravelli; Katherine S Panageas; Jeff Boyd; Benjamin Yeh; Diana E Lake; Chau Dang; Teresa A Gilewski; Jacqueline F Bromberg; Andrew D Seidman; Gabriella D'Andrea-Carlino; Mark M Moasser; Michele Melisko; John W Park; Janet Dancey; Larry Norton; Clifford Hudis
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7878-83.
2008: Alison K Conlin; Andrew D Seidman
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Clinical breast cancer 2008;8(3):215-23.
2008: Blase N Polite; Constance Cirrincione; Gini F Fleming; Donald A Berry; Andrew D Seidman; Hyman Muss; Larry Norton; Charles Shapiro; Kamal Bakri; Paul Kelly Marcom; Diana Lake; Joel H Schwartz; Clifford Hudis; Eric P Winer
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2659-65.
2008: Andrew D Seidman; Donald Berry; Constance Cirrincione; Lyndsay Harris; Hyman Muss; Paul Kelly Marcom; Grandella Gipson; Harold J Burstein; Diana E Lake; Charles L Shapiro; Peter Ungaro; Larry Norton; Eric Winer; Clifford Hudis
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1642-9.
2008: Chau Dang; Monica Fornier; Steven Sugarman; Tiffany Troso-Sandoval; Diana E Lake; Gabriella D'Andrea-Carlino; Andrew D Seidman; Nancy T Sklarin; Maura Dickler; Violante E Currie; Teresa A Gilewski; Mary Ellen Moynahan; P Drullinsky; Mark Robson; Carolyn Wasserheit-Leiblich; Nancy Mills; Richard M Steingart; Katherine S Panageas; Larry Norton; Clifford Hudis
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1216-22.
2007: Gary Deng; Andrew J Vickers; Simon Yeung; Gabriella D'Andrea-Carlino; Han Xiao; Alexandra S Heerdt; Steven Sugarman; Tiffany Troso-Sandoval; Andrew D Seidman; Clifford Hudis; Barrie R Cassileth
Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5584-90.
2007: Alison K Conlin; Andrew D Seidman
Point: combination versus single-agent chemotherapy: the argument for sequential single agents.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(8):668-72.
2007: Monica Arnedos; Andrew D Seidman
Emerging targeted therapies for breast cancer.
Hematology/oncology clinics of North America 2007;21(2):321-40.
2007: Alison K Conlin; Andrew D Seidman
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
Molecular diagnosis & therapy 2007;11(6):355-60.
2007: Monica Fornier; Andrew D Seidman; Diana E Lake; Gabriella D'Andrea-Carlino; Jacqueline F Bromberg; Mark Robson; Catherine Van Poznak; Katherine S Panageas; Marietta Atienza; Larry Norton; Clifford Hudis
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):223-7.
2007: Alison K Conlin; Andrew D Seidman
Taxanes in breast cancer: an update.
Current oncology reports 2007;9(1):22-30.
2006: Jennifer Wheler; Melissa Johnson; Andrew D Seidman
Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Seminars in oncology 2006;33(6):672-80.
2006: Karen Lisa Smith; Chau Dang; Andrew D Seidman
Cardiac dysfunction associated with trastuzumab.
Expert opinion on drug safety 2006;5(5):619-29.
2006: Andrew D Seidman
Systemic treatment of breast cancer. Two decades of progress.
Oncology (Williston Park, N.Y.) 2006;20(9):983-90; discussion 991-2, 997-8.
2006: Shanu Modi; Gabriella D'Andrea-Carlino; Larry Norton; Tzy-Jyun Yao; James Caravelli; Peter P Rosen; Clifford Hudis; Andrew D Seidman
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Clinical breast cancer 2006;7(3):270-7.
2006: Arti Hurria; Anju Hurria; Enid Zuckerman; Katherine S Panageas; Monica Fornier; Gabriella D'Andrea-Carlino; Chau Dang; Mark M Moasser; Mark Robson; Andrew D Seidman; Violante E Currie; Catherine Van Poznak; Maria Theodoulou-Haber; Mark S Lachs; Clifford Hudis
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
Journal of the American Geriatrics Society 2006;54(7):1119-24.
2006: Andrew D Seidman
Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Nature clinical practice. Oncology 2006;3(4):178-9.
2005: Andrew D Seidman
Current status of dose-dense chemotherapy for breast cancer.
Cancer chemotherapy and pharmacology 2005;56 Suppl 1():78-83.
2005: Andrew D Seidman
"Will weekly work"? Seems to be so....
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5873-4.
2005: Melissa L Johnson; Andrew D Seidman
Emerging targeted therapies for breast cancer.
Oncology (Williston Park, N.Y.) 2005;19(5):611-8.
2005: Shanu Modi; Violante E Currie; Andrew D Seidman; Ariadne M Bach; Katherine S Panageas; Maria Theodoulou-Haber; Mark M Moasser; Gabriella D'Andrea-Carlino; Diana E Lake; Jennifer Choi; Larry Norton; Clifford Hudis
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer 2005;6(1):55-60.
2005: Shanu Modi; Andrew D Seidman; Maura Dickler; Mark M Moasser; Gabriella D'Andrea-Carlino; Mary Ellen Moynahan; Jennifer H Menell; Katherine S Panageas; Lee K Tan; Larry Norton; Clifford Hudis
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment 2005;90(2):157-63.
2005: Monica Fornier; Andrew D Seidman; Morton K Schwartz; F Ghani; Robert P Thiel; Larry Norton; Clifford Hudis
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(2):234-9.
2005: Shanu Modi; Michael P DiGiovanna; Zhao Lu; Chaya S Moskowitz; Katherine S Panageas; Catherine Van Poznak; Clifford Hudis; Larry Norton; Lee Tan; David F Stern; Darryl L Carter; Andrew D Seidman
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation 2005;23(6):483-7.
2005: Andrew D Seidman; Larry Norton
Two regimens of docetaxel for metastatic breast cancer.
Current oncology reports 2005;7(1):7.
2004: Andrew D Seidman
Gemcitabine and docetaxel in metastatic breast cancer.
Oncology (Williston Park, N.Y.) 2004;18(14 Suppl 12):13-6.
2004: Debu Tripathy; Andrew D Seidman; Deborah Keefe; Clifford Hudis; Virginia Paton; Grazyna Lieberman
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Clinical breast cancer 2004;5(4):293-8.
2004: Andrew D Seidman
New advances in taxane therapy: the next generation.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 3():S-5-8.
2004: Chau Dang; Gabriella D'Andrea-Carlino; Mary Ellen Moynahan; Maura Dickler; Andrew D Seidman; Monica Fornier; Mark Robson; Maria Theodoulou-Haber; Diana E Lake; Violante E Currie; Arti Hurria; Katherine S Panageas; Larry Norton; Clifford Hudis
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5754-61.
2004: Chau Dang; Andrew J Dannenberg; Kotha Subbaramaiah; Maura Dickler; Mark M Moasser; Andrew D Seidman; Gabriella D'Andrea-Carlino; Maria Theodoulou-Haber; Katherine S Panageas; Larry Norton; Clifford Hudis
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4062-7.
2004: Shanu Modi; Andrew D Seidman
Single-agent gemcitabine in the treatment of advanced breast cancer.
Clinical breast cancer 2004;4 Suppl 3():S101-6.
2003: Andrew D Seidman
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Oncology (Williston Park, N.Y.) 2003;17(12 Suppl 14):9-14.
2003: Maria Theodoulou-Haber; Andrew D Seidman
Cardiac effects of adjuvant therapy for early breast cancer.
Seminars in oncology 2003;30(6):730-9.
2003: Chau Dang; Andrew D Seidman
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
Cancer treatment reviews 2003;29(5):453-6.
2003: Andrew D Seidman
Monotherapy options in the management of metastatic breast cancer.
Seminars in oncology 2003;30(2 Suppl 3):6-10.
2003: Andrew D Seidman
Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):577-9.
2002: Monica Fornier; Mauro Risio; Catherine Van Poznak; Andrew D Seidman
HER2 testing and correlation with efficacy of trastuzumab therapy.
Oncology (Williston Park, N.Y.) 2002;16(10):1340-8, 1351-2; discussion 1352, 1355-8.
2002: Shanu Modi; Katherine S Panageas; Elaine T Duck; Ariadne M Bach; Nancy Weinstock; James Dougherty; Laura D Cramer; Clifford Hudis; Larry Norton; Andrew D Seidman
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3665-73.
2002: Catherine Van Poznak; Lee Tan; Katherine S Panageas; Crispinita D Arroyo; Clifford Hudis; Larry Norton; Andrew D Seidman
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2319-26.
2002: Deborah Toppmeyer; Andrew D Seidman; Michael Pollak; Christy Russell; Katherine Tkaczuk; Shailendra Verma; Beth Overmoyer; Varun Garg; Ene I Ette; Matthew W Harding; George D Demetri
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):670-8.
2002: Andrew D Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Cardiac dysfunction in the trastuzumab clinical trials experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1215-21.
2002: Andrew D Seidman; Joyce O'Shaughnessy; Jean-Louis Misset
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
The oncologist 2002;7 Suppl 6():20-8.
2002: David Miles; Gunter von Minckwitz; Andrew D Seidman
Combination versus sequential single-agent therapy in metastatic breast cancer.
The oncologist 2002;7 Suppl 6():13-9.
2002: Andrew D Seidman; Matti Aapro
Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
The oncologist 2002;7 Suppl 6():1-3.
2002: Catherine Van Poznak; Andrew D Seidman
Critical review of current treatment strategies for advanced hormone insensitive breast cancer.
Cancer investigation 2002;20 Suppl 2():1-14.
2002: Shanu Modi; Andrew D Seidman
An update on epidermal growth factor receptor inhibitors.
Current oncology reports 2002;4(1):47-55.
2001: Monica Fornier; Andrew D Seidman; Maria Theodoulou-Haber; Mary Ellen Moynahan; Violante E Currie; Mark M Moasser; Nancy T Sklarin; Teresa A Gilewski; Gabriella D'Andrea-Carlino; R Salvaggio; Katherine S Panageas; Larry Norton; Clifford Hudis
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3934-41.
2001: Andrew D Seidman; Monica Fornier; Francisco J Esteva; Lee Tan; S Kaptain; Ariadne M Bach; Katherine S Panageas; Crispinita D Arroyo; V Valero; Violante E Currie; Teresa A Gilewski; Maria Theodoulou-Haber; Mary Ellen Moynahan; Mark M Moasser; Nancy T Sklarin; Maura Dickler; Gabriella D'Andrea-Carlino; M Cristofanilli; E Rivera; Gabriel N Hortobagyi; Larry Norton; Clifford Hudis
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2587-95.
2001: Catherine Van Poznak; Andrew D Seidman; MM Reidenberg; Mark M Moasser; Nancy T Sklarin; Kimberly Van Zee; Patrick I Borgen; Marc J Gollub; D Bacotti; Tzy-Jyun Yao; R Bloch; M Ligueros; M Sonenberg; Larry Norton; Clifford Hudis
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
Breast cancer research and treatment 2001;66(3):239-48.
2001: Pamela N Münster; Aman U Buzdar; Kapil Dhingra; N Enas; L Ni; M Major; Allen S Melemed; Andrew D Seidman; Daniel J Booser; Richard Theriault; Larry Norton; Clifford Hudis
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2002-9.
2001: Andrew D Seidman
Gemcitabine as single-agent therapy in the management of advanced breast cancer.
Oncology (Williston Park, N.Y.) 2001;15(2 Suppl 3):11-4.
2001: Andrew D Seidman
Breast disease. Introduction.
Breast disease 2001;14():1.
2001: Brian Leyland-Jones; A Arnold; Karen Gelmon; S Verma; Joseph Ayoub; Andrew D Seidman; R Dias; J Howell; A Rakhit
Pharmacologic insights into the future of trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12 Suppl 1():S43-7.
2001: Andrew D Seidman
The evolving role of gemcitabine in the management of breast cancer.
Oncology 2001;60(3):189-98.
2000: Monica Fornier; Francisco J Esteva; Andrew D Seidman
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Seminars in oncology 2000;27(6 Suppl 11):38-45; discussion 92-100.
2000: José Baselga; David G Pfister; M Robert Cooper; R Cohen; B Burtness; M Bos; Gabriella D'Andrea-Carlino; Andrew D Seidman; Larry Norton; K Gunnett; J Falcey; V Anderson; Harlan W Waksal; John Mendelsohn
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):904-14.
2000: Teresa A Gilewski; Andrew D Seidman; Larry Norton; Clifford Hudis
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S23-6.
1999: José Baselga; Debu Tripathy; John Mendelsohn; S Baughman; C C Benz; L Dantis; Nancy T Sklarin; Andrew D Seidman; Clifford Hudis; J Moore; Paul Peter Rosen; T Twaddell; I Craig Henderson; Larry Norton
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):78-83.
1999: Andrew D Seidman
Single-agent paclitaxel in the treatment of breast cancer: phase I and II development.
Seminars in oncology 1999;26(3 Suppl 8):14-20.
1999: Monica Fornier; Pamela N Munster; Andrew D Seidman
Update on the management of advanced breast cancer.
Oncology (Williston Park, N.Y.) 1999;13(5):647-58; discussion 660, 663-4.
1999: Clifford Hudis; Monica Fornier; L Riccio; David Lebwohl; John Crown; Teresa A Gilewski; A Surbone; Violante E Currie; Andrew D Seidman; B Reichman; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; Maria Theodoulou-Haber; L Weiselberg; R Salvaggio; Katherine S Panageas; Tzy-Jyun Yao; Larry Norton
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1118.
1999: Gabriella D'Andrea-Carlino; DW Fennelly; Larry Norton; José Baselga; Teresa A Gilewski; Clifford Hudis; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; A Surbone; Maria Theodoulou-Haber; M A Templeton; Tzy-Jyun Yao; Andrew D Seidman
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):275-9.
1999: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly; John Crown; A Surbone; M Uhlenhopp; Elyn Riedel; Tzy-Jyun Yao; Larry Norton
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):93-100.
1998: Andrew D Seidman; Clifford Hudis; J Albanell; J Albanel; William Tong; I Tepler; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; Marc J Gollub; José Baselga; Larry Norton
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3353-61.
1998: Andrew D Seidman
One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index.
Oncology (Williston Park, N.Y.) 1998;12(1 Suppl 1):19-22.
1998: Clifford Hudis; L Riccio; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; David Lebwohl; Mary Ellen Moynahan; G Raptis; A Surbone; Nancy T Sklarin; Tzy-Jyun Yao; Deborah Keefe; Larry Norton
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Cancer investigation 1998;16(2):67-71.
1998: René Bruno; D Hille; A Riva; Nicole Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; James R Rigas; Andrew D Seidman; B Chevallier; P Fumoleau; H A Burris; Peter M Ravdin; L B Sheiner
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):187-96.
1997: P Fumoleau; Andrew D Seidman; M E Trudeau; B Chevallier; W W Ten Bokkel Huinink
Docetaxel: a new active agent in the therapy of metastatic breast cancer.
Expert opinion on investigational drugs 1997;6(12):1853-65.
1997: Clifford Hudis; L Riccio; F Holmes; Andrew D Seidman; José Baselga; Violante E Currie; DW Fennelly; Teresa A Gilewski; Mary Ellen Moynahan; G Raptis; Nancy T Sklarin; A Surbone; M Uhlenhopp; N Maickel; Tzy-Jyun Yao; S Hellmann; J Usakewicz; Gabriel N Hortobagyi; Larry Norton
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(13):2198-202.
1997: Andrew D Seidman; Clifford Hudis; John McCaffrey; William Tong; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; I Tepler; Marc J Gollub; Larry Norton
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-72-S17-76.
1997: Peter A Forsyth; Casilda Balmaceda; Kendra Peterson; Andrew D Seidman; P M A Brasher; Lisa De Angelis
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
Journal of neuro-oncology 1997;35(1):47-53.
1997: Gabriella D'Andrea-Carlino; Andrew D Seidman
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
Seminars in oncology 1997;24(4 Suppl 13):S13-27-S13-44.
1997: José Baselga; Andrew D Seidman; Paul Peter Rosen; Larry Norton
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):43-8.
1997: Andrew D Seidman; Clifford Hudis; G Raptis; José Baselga; DW Fennelly; Larry Norton
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
Oncology (Williston Park, N.Y.) 1997;11(3 Suppl 2):20-8.
1996: J Ingham; Andrew D Seidman; Tzy-Jyun Yao; J Lepore; Russell Portenoy
An exploratory study of frequent pain measurement in a cancer clinical trial.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1996;5(5):503-7.
1996: R J Freilich; Casilda Balmaceda; Andrew D Seidman; M Rubin; Lisa De Angelis
Motor neuropathy due to docetaxel and paclitaxel.
Neurology 1996;47(1):115-8.
1996: Andrew D Seidman; Daniel Hochhauser; Marc J Gollub; B Edelman; Tzy-Jyun Yao; Clifford Hudis; P Francis; DW Fennelly; Teresa A Gilewski; Mary Ellen Moynahan; Violante E Currie; José Baselga; William Tong; M O'Donaghue; R Salvaggio; L Auguste; David Spriggs; Larry Norton
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1877-84.
1996: José Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; Nancy T Sklarin; Andrew D Seidman; Clifford Hudis; J Moore; Paul Peter Rosen; T Twaddell; I C Henderson; Larry Norton
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):737-44.
1996: Clifford Hudis; Andrew D Seidman; G Raptis; DW Fennelly; Teresa A Gilewski; José Baselga; Maria Theodoulou-Haber; Nancy T Sklarin; Mary Ellen Moynahan; A Surbone; Violante E Currie; David Lebwohl; M Uhlenhopp; John Crown; Larry Norton
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Seminars in oncology 1996;23(1 Suppl 1):58-64.
1996: Andrew D Seidman
Chemotherapy for advanced breast cancer: a current perspective.
Seminars in oncology 1996;23(1 Suppl 2):55-9.
1996: Clifford Hudis; Andrew D Seidman; John Crown; Casilda Balmaceda; R Freilich; Teresa A Gilewski; T B Hakes; Violante E Currie; David Lebwohl; José Baselga; G Raptis; Marc J Gollub; M Robles; R Bruno; Larry Norton
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):58-65.
1995: Clifford Hudis; Andrew D Seidman; José Baselga; G Raptis; David Lebwohl; Teresa A Gilewski; Violante E Currie; Mary Ellen Moynahan; Nancy T Sklarin; DW Fennelly
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Seminars in oncology 1995;22(6 Suppl 15):18-23.
1995: Andrew D Seidman
Paclitaxel: the long and short of it.
The cancer journal from Scientific American 1995;1(4):250-1.
1995: Andrew D Seidman; A Tiersten; Clifford Hudis; Marc J Gollub; S Barrett; Tzy-Jyun Yao; J Lepore; Teresa A Gilewski; Violante E Currie; John Crown
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2575-81.
1995: Andrew D Seidman; Clifford Hudis; DW Fennelly; G Raptis; José Baselga; Larry Norton
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
Seminars in oncology 1995;22(5 Suppl 12):108-16.
1995: Andrew D Seidman; Russell Portenoy; Tzy-Jyun Yao; J Lepore; E K Mont; Jeremy Kortmansky; N Onetto; L Ren; J Grechko; M Beltangady
Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.
Journal of the National Cancer Institute 1995;87(17):1316-22.
1995: Andrew D Seidman; Clifford Hudis; Larry Norton
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Seminars in oncology 1995;22(4 Suppl 8):3-8.
1995: R J Freilich; Andrew D Seidman; Lisa De Angelis
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel.
Cancer 1995;76(2):232-6.
1995: R J Freilich; Andrew D Seidman
Pruritus caused by 3-hour infusion of high-dose paclitaxel and improvement with tricyclic antidepressants.
Journal of the National Cancer Institute 1995;87(12):933-4.
1995: Andrew D Seidman; B S Reichman; John Crown; Tzy-Jyun Yao; Violante E Currie; T B Hakes; Clifford Hudis; Teresa A Gilewski; José Baselga; P Forsythe
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1152-9.
1995: Andrew D Seidman
The emerging role of paclitaxel in breast cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(3):247-56.
1994: J A Schneider; Chaitanya R Divgi; A M Scott; Homer A Macapinlac; Andrew D Seidman; S J Goldsmith; Steven M Larson
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(11):1748-52.
1994: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; T B Hakes; David Lebwohl; Teresa A Gilewski; Clifford Hudis; A Surbone
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Oncology 1994;51 Suppl 1():33-9.
1994: Andrew D Seidman; S Barrett; S Canezo
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1741-2.
1994: P K Schultz; Harry W Herr; Zuo-Feng Zhang; Dean F Bajorin; Andrew D Seidman; A Sarkis; W R Fair; D Scherr; George J Bosl; Howard I Scher
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1394-401.
1994: R Foa; Larry Norton; Andrew D Seidman
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
International journal of clinical & laboratory research 1994;24(1):6-14.
1994: Andrew D Seidman
Single-agent use of Taxol (paclitaxel) in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S17-22.
1993: B S Reichman; Andrew D Seidman; John Crown; Robert T Heelan; Tzy-Jyun Yao; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.
Annals of the New York Academy of Sciences 1993;698():398-402.
1993: B S Reichman; Andrew D Seidman; John Crown; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie; Clifford Hudis
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1943-51.
1993: Andrew D Seidman; Larry Norton; B S Reichman; John Crown; Tzy-Jyun Yao; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Seminars in oncology 1993;20(4 Suppl 3):40-5.
1993: Andrew D Seidman; Howard I Scher; JL Gabrilove; Dean F Bajorin; Robert J Motzer; M O'Dell; T Curley; D David Dershaw; S Quinlivan; Y Tao
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(3):408-14.
1993: John Crown; T Hakes; B Reichman; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie; Tzy-Jyun Yao; Clifford Hudis; Andrew D Seidman
Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Cancer 1993;71(4):1254-7.
1993: Andrew D Seidman; M Schwartz; Lilian Reich; Howard I Scher
Immune-mediated thrombocytopenia secondary to suramin.
Cancer 1993;71(3):851-4.
1993: Andrew D Seidman; B S Reichman; John Crown; Tzy-Jyun Yao; Robert T Heelan; T B Hakes; David Lebwohl; Teresa A Gilewski; A Surbone; Violante E Currie
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.
Journal of the National Cancer Institute. Monographs 1993;(15):171-5.
1992: Andrew D Seidman; Howard I Scher; D Petrylak; D David Dershaw; T Curley
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
The Journal of urology 1992;147(3 Pt 2):931-4.
1991: Andrew D Seidman; Howard I Scher; M H Heinemann; Dean F Bajorin; C N Sternberg; D David Dershaw; M Silverberg; George J Bosl
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.
Cancer 1991;68(12):2561-5.
1991: Andrew D Seidman; Howard I Scher
The evolving role of chemotherapy for muscle infiltrating bladder cancer.
Seminars in oncology 1991;18(6):585-95.